Status:
COMPLETED
A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Tumors
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
A study to evaluate biomarkers of cancer (context-specific sensitizers) in the skin of participants already receiving cytotoxic therapy. Additional blood and urine samples will be collected for phosph...
Eligibility Criteria
Inclusion
- Participant has solid tumor that will be treated with one of the following treatments:
- Gemcitabine monotherapy
- Cisplatin monotherapy
- Carboplatin monotherapy
- Gemcitabine and cisplatin combination therapy
- Gemcitabine and erlotinib combination therapy
- Gemcitabine and carboplatin combination therapy
- Cisplatin and vinorelbine combination therapy
- Cisplatin and pemetrexed combination therapy
- Carboplatin and vinorelbine combination therapy
- Carboplatin and pemetrexed combination therapy
Exclusion
- Participant has had recent cancer treatments including chemotherapy or radiation
- Participant has been in an investigational study within the last 30 days
- Participant has a history of drug or alcohol abuse
- Participant is Human Immunodeficiency Virus (HIV) positive or has a history of Hepatitis B or C
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00800865
Start Date
January 1 2009
End Date
October 1 2009
Last Update
November 3 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.